AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS WHO WERE PREVIOUSLY ENROLLED IN PROTOCOL 0881A1-3338-WW(B1801014)
Latest Information Update: 09 May 2023
At a glance
- Drugs Etanercept (Primary)
- Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
- Focus Adverse reactions
- Acronyms CLIPPER2
- Sponsors Pfizer
- 04 May 2023 Results of Ten-year safety and clinical benefit from CLIPPER and CLIPPER 2, published in the Rheumatology
- 04 Jun 2022 Results assessing the safety of ETN in this population after 10 years of follow up presented at the 23rd Annual Congress of the European League Against Rheumatism
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism